Caladrius CEO Predicts Tenfold Market Cap Rise As Pipeline ‘Validates’ Itself

With its first product on track for approval soon in Japan, Caladrius Biosciences Inc. is planning its transition over the next three years from a late-stage developer of cell therapies to one commercializing treatments for ischemic diseases. The evolution should see the US group’s share price rise steadily as its pipeline "validates itself", CEO David Mazzo told Scrip.

Caladrius Biosciences has product candidates in development based on two technology platforms, one targeting autoimmune and one targeting cardiology indications.